Uncategorized
Eylea continues to be a strong franchise for Regeneron
Eylea saw $3.32 billion in U.S. net sales for 2016, and global sales of the neovascular age-related macular degeneration treatment reached more than $5.52 billion, according to a speaker at the 35th Annual J.P. Morgan Healthcare Conference.The full-year net sales in the U.S. for Eylea (aflibercept, Regeneron) increased by 24% year over year, on the higher end of what Regeneron expected in sales for 2016, Leonard S. Schleifer, MD, PhD, president and CEO of Regeneron, said at the conference.